During the last budget period, the Cancer Center has undergone an expansive reorganization of its administrative, scientific and educational goals and initiatives. Guided by a comprehensive and inclusive strategic planning process that engaged all ofthe stakeholders ofthe cancer research enterprise, comprehensive directives were implemented that realigned scientific Programs for multidisciplinary collaboration, reorganized Shared Resources for optimal impact and penetration, launched a portfolio of educational and mentoring initiatives and created inter-institutional partnerships along the continuum of basic, translational and patient-oriented cancer research. One of the key strategic directives of the consultative process was the creation of a dedicated administrative infrastructure ideally suited to guide the anticipated expansion ofthe Cancer Center during the next CCSG budget period, coinciding with the opening of the new Wistar Research Tower This resulted in the creation of a new Cancer Center leadership team, the reorganization of consultative and advisory venues, the appointment of new advisory committees, and the creation of a new Cancer Center-dedicated External Advisory Board. As emerged from the strategic planning process, this newly reconfigured, integrated administrative infrastructure provided a lean and opportunity-driven decision-making process for the Cancer Center. This was instrumental to enable a broad range of successful initiatives during the last budget period, which positioned the Cancer Center on a steep ascending trajectory with respect to growth of NCI and cancer-related funding, increase in collaborative publications and seminal scientific discoveries in basic and translational cancer research. This positive trajectory will continue in the next budget period, as the newly reconfigured Cancer Center administrative infrastructure will lead the upcoming faculty and facility expansion, expand education and mentoring activities, including outreach to underrepresented minorities, and support multidisciplinary initiatives in basic and translational cancer research

Public Health Relevance

In past CCSG budget periods, the Wistar Institute and its NCI-designated Cancer Center shared entirely their administrative infrastructure and decision-making venues. This has now changed as part ofthe comprehensive reorganization ofthe Cancer Center, and a dedicated administrative and leadership team is now in place to advance the cancer research agenda in the upcoming facility and faculty expansion

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA010815-49
Application #
9438879
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
49
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51
Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560
Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Noguchi, Shuhei; Arakawa, Takahiro; Fukuda, Shiro et al. (2017) FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112

Showing the most recent 10 out of 685 publications